NCT05273047 (LungKG12Ci) is a clinical trial in Nsclc, sponsored by Intergroupe Francophone de Cancerologie Thoracique.

Who is sponsoring NCT05273047?

NCT05273047 is sponsored by Intergroupe Francophone de Cancerologie Thoracique.

What condition does NCT05273047 study?

NCT05273047 studies Nsclc, KRAS P.G12C.

Is NCT05273047 still recruiting?

NCT05273047 is currently status unknown. Last updated 29 September 2023.

Last reviewed 2023-09-29 · How we verify

NCT05273047: LungKG12Ci

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Status unknown Last updated 29 September 2023

What this trial tests

trial in Nsclc in 458 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
30 August 2023

31 December 2024

Quick facts

Lead sponsor	Intergroupe Francophone de Cancerologie Thoracique
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	458
Start date	1 March 2022
Primary completion	30 August 2023
Estimated completion	31 December 2024
Sites	3 locations across France

Conditions studied

Nsclc — all drugs for Nsclc →
KRAS P.G12C — all drugs for KRAS P.G12C →

Sponsor

Intergroupe Francophone de Cancerologie Thoracique — full company profile →

Who can join

Adults 18 to 90, any sex, with Nsclc or KRAS P.G12C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU applications in order to collect retrospectively, as soon as possible after inclusion and under real-life conditions, the efficacy data on sotorasib (AMG 510) as well as the demographic and molecular characteristics of patients.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

The current state of the art and future trends in RAS-targeted cancer therapies.
Punekar SR, Velcheti V, Neel BG, Wong KK. · · 2022 · cited 382× · PMID 36028717 · DOI 10.1038/s41571-022-00671-9
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Lu Y, Yang Y, Zhu G, Zeng H, et al · · 2023 · cited 24× · PMID 37496997 · DOI 10.7150/ijbs.83026
Direct GDP-KRAS<sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg.
Rosen JC, Sacher A, Tsao MS. · · 2023 · cited 15× · PMID 36950276 · DOI 10.1177/17588359231160141
How to manage <i>KRAS</i> G12C-mutated advanced non-small-cell lung cancer.
Ricciuti B, Mira A, Andrini E, Scaparone P, et al · · 2022 · cited 10× · PMID 36452878 · DOI 10.7573/dic.2022-7-4
First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.
He Q, Liu X, Jiang L, Liu P, et al · · 2025 · cited 8× · PMID 39681355 · DOI 10.1080/15384047.2024.2441499
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.
Choucair K, Imtiaz H, Uddin MH, Nagasaka M, et al · · 2025 · cited 4× · PMID 41309533 · DOI 10.1038/s41392-025-02473-8

Verify or expand the search:

Other recruiting trials for Nsclc

Currently open trials in the same condition.

NCT05378633 — The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Br · NA · recruiting
NCT05165160 — Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis · NA · active not recruiting
NCT04585490 — Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in S · Phase 3 · recruiting

Other Intergroupe Francophone de Cancerologie Thoracique trials

Trials by the same sponsor.

NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting
NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
NCT06840834 — Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previo · Phase 2 · recruiting
NCT05285033 — RW Effectiveness of Lurbinectedin in Extensive Stage SCLC · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05273047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Intergroupe Francophone de Cancerologie Thoracique
Last refreshed: 29 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05273047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing